Welcome in the research database

Cansearch Researc Laboratory.

The group works manly on two topics in 2013

Pharmaco-oncogenetics :
Dr. Marc Ansari worked in the field of pediatric oncogenetics at the St Justine Hospital (Montréal, Canada) between 2004 and september 2007 thanks to the financial support of the Swiss National Science Foundation. In 2007 he joinedthe CMU, where he continued his research on the polymorphism of certain genes involved in the metabolism of Busulfan, the main chemotherapeutic agent used in hematopoietic stem cell transplantation. He could demonstrate that the genetic polymorphisms in certain genes that control the enzymes involved in the metabolism of Busulfan are responsible for the efficiency and the toxicity of this agent. This project has been accepted as a multicentric study by the European Group for Blood and Marrow Transplantation (EBMT). These scientific works allow for decreasing drug toxicity and increasing outcome in children with cancer. Thanks to these works, medication can be adapted according to specific genes (individualized therapy).

Oncogenetics :
The group works as well on the ATM (Ataxia Telangiectasia Mutated) tumor suppressor gene. Through collaboration with the Children's Oncology Group (USA) Dr Gumy-Pause obtained a large number of tumor samples necessary to her research. At first, her work focused on leukemia and lymphoma in childhood (mainly thanks to the support of the Dubois-Ferrière-Dinu Lipatti Foundation), then on neuroblastoma. She could demonstrate that in neuroblastoma, ATM loss occurs frequently and, in addition, is a likely marker of bad prognosis. On the long-term, the aim of her research work is to adapt the treatment to the genotype of the tumor and to develop new therapeutic strategies.

Dr Ansari created the CANSEARCH foundation to support his research laboratory. For more informations and to find annual report please visit www.cansearch.ch

Group's publications

Pseudoprogression after proton beam irradiation for a choroid plexus carcinoma in pediatric patient: MRI and PET imaging patterns.
CHILD'S NERVOUS SYSTEM : CHNS : OFFICIAL JOURNAL OF THE INTERNATIONAL SOCIETY FOR PEDIATRIC NEUROSURGERY
2013 vol. 29(3) pp. 509-512
KORCHI AM, GARIBOTTO V, ANSARI M, MERLINI L

Is acute fibrinous and organizing pneumonia the expression of immune dysregulation?
JOURNAL OF PEDIATRIC HEMATOLOGY/ONCOLOGY : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF PEDIATRIC HEMATOLOGY/ONCOLOGY
2013 vol. 35(2) pp. 139-143
LABARINAS S, GUMY PAUSE F, ROUGEMONT AL, BAERLOCHER G, LEIBUNDGUT EO, PORRET N, SCHÄPPI MG, BARAZZONE-ARGIROFFO C, PASSWEG J, MERLINI L, OZSAHIN H, ANSARI M

Validation of SYBR Green based quantification assay for the detection of human Torque Teno virus titers from plasma.
VIROLOGY JOURNAL
2013 vol. 10(1) pp. 191-191
TYAGI AK, PRADIER A, BAUMER O, UPPUGUNDURI CR, HUEZO-DIAZ P, POSFAY-BARBE K, ROOSNEK E, ANSARI M

A novel method for quantification of sulfolane (a metabolite of busulfan) in plasma by gas chromatography-tandem mass spectrometry.
ANALYTICAL AND BIOANALYTICAL CHEMISTRY
2012 vol. 404(6-7) pp. 1831-1838
VERSACE F, UPPUGUNDURI CR, KRAJINOVIC M, THÉORÊT Y, GUMY PAUSE F, MANGIN P, STAUB C, ANSARI M

Transcriptional regulation of CYP2C19 and its role in altered enzyme activity.
CURRENT DRUG METABOLISM
2012 vol. 13(8) pp. 1196-1204
UPPUGUNDURI CR, DAALI Y, DESMEULES J, DAYER P, KRAJINOVIC M, ANSARI M

Influence of age, sex, and haplotypes of thiopurine methyltransferase (TPMT) gene on 6- mercaptopurine toxicity in children with acute lymphoblastic leukemia.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
2012 vol. 68(5) pp. 887-888
UPPUGUNDURI CR, ANSARI M

GSTP1 hypermethylation is associated with reduced protein expression, aggressive disease and prognosis in neuroblastoma.
GENES, CHROMOSOMES & CANCER
2012 vol. 51(2) pp. 174-185
GUMY PAUSE F, PARDO B, KHOSHBEEN-BOUDAL M, ANSARI M, GAYET-AGERON A, SAPPINO AP, ATTIYEH EF, OZSAHIN H

Secondary pulmonary alveolar proteinosis after unrelated cord blood hematopoietic cell transplantation.
PEDIATRIC TRANSPLANTATION
2012 vol. 16(5) pp. 146-149
ANSARI M, ROUGEMONT AL, LE DEIST F, OZSAHIN H, DUVAL M, CHAMPAGNE MA, FOURNET JC

Third-party mesenchymal stromal cell infusion is associated with a decrease in thrombotic microangiopathy symptoms observed post-hematopoietic stem cell transplantation.
PEDIATRIC TRANSPLANTATION
2012 vol. 16(2) pp. 131-136
ANSARI M, STRUNK D, SCHALLMOSER K, DELCO C, ROUGEMONT AL, MOLL S, VILLARD J, GUMY PAUSE F, CHALANDON Y, PARVEX P, PASSWEG J, OZSAHIN H, KINDLER V

A simplified method for busulfan monitoring using dried blood spot in combination with liquid chromatography/tandem mass spectrometry.
RAPID COMMUNICATIONS IN MASS SPECTROMETRY : RCM
2012 vol. 26(12) pp. 1437-1446
ANSARI M, UPPUGUNDURI CR, DÉGLON J, THÉORÊT Y, VERSACE F, GUMY PAUSE F, OZSAHIN H, DAYER P, DESMEULES J, DAALI Y

Outcome and risk factors for late-onset complications 24 months beyond allogeneic hematopoietic stem cell transplantation.
EUROPEAN JOURNAL OF HAEMATOLOGY
2011 vol. 87(2) pp. 138-147
BIERI S, ROOSNEK E, OZSAHIN H, HUGUET S, ANSARI M, TROMBETTI A, HELG C, CHAPUIS B, MIRALBELL R, PASSWEG J, CHALANDON Y

Primary leptomeningeal melanocytosis in a 10-year-old girl: a challenging diagnosis with a poor prognosis.
JOURNAL OF CHILD NEUROLOGY
2011 vol. 26(11) pp. 1444-1448
BRUNSVIG KL, ZENOBI M, RILLIET B, EL HASSANI Y, DE HALLER R, ANSARI M, LOBRINUS JA, HANQUINET S, FLUSS J

Acute disseminated fatal toxoplasmosis after haploidentical stem cell transplantation despite atovaquone prophylaxis in a young man.
PEDIATRIC INFECTIOUS DISEASE JOURNAL
2010 vol. 29(11) pp. 1059-1060
GARCIA DE LA FUENTE I, ANSARI M, ROUGEMONT AL, PASSWEG J, GUMY PAUSE F, OZSAHIN H, LOBRINUS JA, POSFAY-BARBE K

Polymorphisms in multidrug resistance-associated protein gene 4 is associated with outcome in childhood acute lymphoblastic leukemia.
BLOOD
2009 vol. 114(7) pp. 1383-1386
ANSARI M, SAUTY G, LABUDA M, GAGNÉ V, LAVERDIÈRE C, MOGHRABI A, SINNETT D, KRAJINOVIC M

DNA variants in region for noncoding interfering transcript of dihydrofolate reductase gene and outcome in childhood acute lymphoblastic leukemia.
CLINICAL CANCER RESEARCH
2009 vol. 15(22) pp. 6931-6938
AL-SHAKFA F, DULUCQ S, BRUKNER I, MILACIC I, ANSARI M, BEAULIEU P, MOGHRABI A, LAVERDIÈRE C, SALLAN SE, SILVERMAN LB, NEUBERG D, KUTOK JL, SINNETT D, KRAJINOVIC M

Can the pharmacogenetics of GST gene polymorphisms predict the dose of busulfan in pediatric hematopoietic stem cell transplantation?
PHARMACOGENETICS
2009 vol. 10(11) pp. 1729-1732
ANSARI M, KRAJINOVIC M

IV busulfan dose individualization in children undergoing hematopoietic stem cell transplant: limited sampling strategies.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
2008 vol. 14(5) pp. 576-582
DUPUIS LL, SIBBALD C, SCHECHTER T, ANSARI M, GASSAS A, THÉORÊT Y, KASSIR N, CHAMPAGNE MA, DOYLE J

DNA variants in the dihydrofolate reductase gene and outcome in childhood ALL.
BLOOD
2008 vol. 111(7) pp. 3692-3700
DULUCQ S, ST-ONGE G, GAGNÉ V, ANSARI M, SINNETT D, LABUDA D, MOGHRABI A, KRAJINOVIC M

Pharmacogenomics in cancer treatment defining genetic bases for inter-individual differences in responses to chemotherapy.
CURRENT OPINION IN PEDIATRICS
2007 vol. 19(1) pp. 15-22
ANSARI M, KRAJINOVIC M

Pharmacogenomics of acute leukemia.
PHARMACOGENOMICS
2007 vol. 8(7) pp. 817-834
ANSARI M, KRAJINOVIC M

Research's domains

TUMOR SUPPRESSOR GENE
PHARMACOGENETICS
STEM CELLS TRANSPLANTATION
ONCOLOGY AND PEDIATRICS HEMATOLOGY
ONCOGENTICS




DATABASE-RESEARCH	GROUP OF CLINICAL PATIENT RESEARCH

Mr Ansari Marc	Head of group CV	Research subject	Members of the group


	Links about the group Dr. M. Ansari HUG/Dpt Enfant Adolescent Ser.pédia.générale/La Tulipe Avenue de la Roseraie 64 1205 Genève Marc.Ansari@hcuge.ch Tel.: +41 22 372 47 31 Fax: +41 22 382 31 00 Group's web site / department Comments Pages updated the 17.11.2015		Reseach's subject \| Group's publications \| Research's domains Cansearch Researc Laboratory. The group works manly on two topics in 2013 Pharmaco-oncogenetics : Dr. Marc Ansari worked in the field of pediatric oncogenetics at the St Justine Hospital (Montréal, Canada) between 2004 and september 2007 thanks to the financial support of the Swiss National Science Foundation. In 2007 he joinedthe CMU, where he continued his research on the polymorphism of certain genes involved in the metabolism of Busulfan, the main chemotherapeutic agent used in hematopoietic stem cell transplantation. He could demonstrate that the genetic polymorphisms in certain genes that control the enzymes involved in the metabolism of Busulfan are responsible for the efficiency and the toxicity of this agent. This project has been accepted as a multicentric study by the European Group for Blood and Marrow Transplantation (EBMT). These scientific works allow for decreasing drug toxicity and increasing outcome in children with cancer. Thanks to these works, medication can be adapted according to specific genes (individualized therapy). Oncogenetics : The group works as well on the ATM (Ataxia Telangiectasia Mutated) tumor suppressor gene. Through collaboration with the Children's Oncology Group (USA) Dr Gumy-Pause obtained a large number of tumor samples necessary to her research. At first, her work focused on leukemia and lymphoma in childhood (mainly thanks to the support of the Dubois-Ferrière-Dinu Lipatti Foundation), then on neuroblastoma. She could demonstrate that in neuroblastoma, ATM loss occurs frequently and, in addition, is a likely marker of bad prognosis. On the long-term, the aim of her research work is to adapt the treatment to the genotype of the tumor and to develop new therapeutic strategies. Dr Ansari created the CANSEARCH foundation to support his research laboratory. For more informations and to find annual report please visit www.cansearch.ch Group's publications Pseudoprogression after proton beam irradiation for a choroid plexus carcinoma in pediatric patient: MRI and PET imaging patterns. CHILD'S NERVOUS SYSTEM : CHNS : OFFICIAL JOURNAL OF THE INTERNATIONAL SOCIETY FOR PEDIATRIC NEUROSURGERY 2013 vol. 29(3) pp. 509-512 KORCHI AM, GARIBOTTO V, ANSARI M, MERLINI L Is acute fibrinous and organizing pneumonia the expression of immune dysregulation? JOURNAL OF PEDIATRIC HEMATOLOGY/ONCOLOGY : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF PEDIATRIC HEMATOLOGY/ONCOLOGY 2013 vol. 35(2) pp. 139-143 LABARINAS S, GUMY PAUSE F, ROUGEMONT AL, BAERLOCHER G, LEIBUNDGUT EO, PORRET N, SCHÄPPI MG, BARAZZONE-ARGIROFFO C, PASSWEG J, MERLINI L, OZSAHIN H, ANSARI M Validation of SYBR Green based quantification assay for the detection of human Torque Teno virus titers from plasma. VIROLOGY JOURNAL 2013 vol. 10(1) pp. 191-191 TYAGI AK, PRADIER A, BAUMER O, UPPUGUNDURI CR, HUEZO-DIAZ P, POSFAY-BARBE K, ROOSNEK E, ANSARI M A novel method for quantification of sulfolane (a metabolite of busulfan) in plasma by gas chromatography-tandem mass spectrometry. ANALYTICAL AND BIOANALYTICAL CHEMISTRY 2012 vol. 404(6-7) pp. 1831-1838 VERSACE F, UPPUGUNDURI CR, KRAJINOVIC M, THÉORÊT Y, GUMY PAUSE F, MANGIN P, STAUB C, ANSARI M Transcriptional regulation of CYP2C19 and its role in altered enzyme activity. CURRENT DRUG METABOLISM 2012 vol. 13(8) pp. 1196-1204 UPPUGUNDURI CR, DAALI Y, DESMEULES J, DAYER P, KRAJINOVIC M, ANSARI M Influence of age, sex, and haplotypes of thiopurine methyltransferase (TPMT) gene on 6- mercaptopurine toxicity in children with acute lymphoblastic leukemia. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 2012 vol. 68(5) pp. 887-888 UPPUGUNDURI CR, ANSARI M GSTP1 hypermethylation is associated with reduced protein expression, aggressive disease and prognosis in neuroblastoma. GENES, CHROMOSOMES & CANCER 2012 vol. 51(2) pp. 174-185 GUMY PAUSE F, PARDO B, KHOSHBEEN-BOUDAL M, ANSARI M, GAYET-AGERON A, SAPPINO AP, ATTIYEH EF, OZSAHIN H Secondary pulmonary alveolar proteinosis after unrelated cord blood hematopoietic cell transplantation. PEDIATRIC TRANSPLANTATION 2012 vol. 16(5) pp. 146-149 ANSARI M, ROUGEMONT AL, LE DEIST F, OZSAHIN H, DUVAL M, CHAMPAGNE MA, FOURNET JC Third-party mesenchymal stromal cell infusion is associated with a decrease in thrombotic microangiopathy symptoms observed post-hematopoietic stem cell transplantation. PEDIATRIC TRANSPLANTATION 2012 vol. 16(2) pp. 131-136 ANSARI M, STRUNK D, SCHALLMOSER K, DELCO C, ROUGEMONT AL, MOLL S, VILLARD J, GUMY PAUSE F, CHALANDON Y, PARVEX P, PASSWEG J, OZSAHIN H, KINDLER V A simplified method for busulfan monitoring using dried blood spot in combination with liquid chromatography/tandem mass spectrometry. RAPID COMMUNICATIONS IN MASS SPECTROMETRY : RCM 2012 vol. 26(12) pp. 1437-1446 ANSARI M, UPPUGUNDURI CR, DÉGLON J, THÉORÊT Y, VERSACE F, GUMY PAUSE F, OZSAHIN H, DAYER P, DESMEULES J, DAALI Y Outcome and risk factors for late-onset complications 24 months beyond allogeneic hematopoietic stem cell transplantation. EUROPEAN JOURNAL OF HAEMATOLOGY 2011 vol. 87(2) pp. 138-147 BIERI S, ROOSNEK E, OZSAHIN H, HUGUET S, ANSARI M, TROMBETTI A, HELG C, CHAPUIS B, MIRALBELL R, PASSWEG J, CHALANDON Y Primary leptomeningeal melanocytosis in a 10-year-old girl: a challenging diagnosis with a poor prognosis. JOURNAL OF CHILD NEUROLOGY 2011 vol. 26(11) pp. 1444-1448 BRUNSVIG KL, ZENOBI M, RILLIET B, EL HASSANI Y, DE HALLER R, ANSARI M, LOBRINUS JA, HANQUINET S, FLUSS J Acute disseminated fatal toxoplasmosis after haploidentical stem cell transplantation despite atovaquone prophylaxis in a young man. PEDIATRIC INFECTIOUS DISEASE JOURNAL 2010 vol. 29(11) pp. 1059-1060 GARCIA DE LA FUENTE I, ANSARI M, ROUGEMONT AL, PASSWEG J, GUMY PAUSE F, OZSAHIN H, LOBRINUS JA, POSFAY-BARBE K Polymorphisms in multidrug resistance-associated protein gene 4 is associated with outcome in childhood acute lymphoblastic leukemia. BLOOD 2009 vol. 114(7) pp. 1383-1386 ANSARI M, SAUTY G, LABUDA M, GAGNÉ V, LAVERDIÈRE C, MOGHRABI A, SINNETT D, KRAJINOVIC M DNA variants in region for noncoding interfering transcript of dihydrofolate reductase gene and outcome in childhood acute lymphoblastic leukemia. CLINICAL CANCER RESEARCH 2009 vol. 15(22) pp. 6931-6938 AL-SHAKFA F, DULUCQ S, BRUKNER I, MILACIC I, ANSARI M, BEAULIEU P, MOGHRABI A, LAVERDIÈRE C, SALLAN SE, SILVERMAN LB, NEUBERG D, KUTOK JL, SINNETT D, KRAJINOVIC M Can the pharmacogenetics of GST gene polymorphisms predict the dose of busulfan in pediatric hematopoietic stem cell transplantation? PHARMACOGENETICS 2009 vol. 10(11) pp. 1729-1732 ANSARI M, KRAJINOVIC M IV busulfan dose individualization in children undergoing hematopoietic stem cell transplant: limited sampling strategies. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION 2008 vol. 14(5) pp. 576-582 DUPUIS LL, SIBBALD C, SCHECHTER T, ANSARI M, GASSAS A, THÉORÊT Y, KASSIR N, CHAMPAGNE MA, DOYLE J DNA variants in the dihydrofolate reductase gene and outcome in childhood ALL. BLOOD 2008 vol. 111(7) pp. 3692-3700 DULUCQ S, ST-ONGE G, GAGNÉ V, ANSARI M, SINNETT D, LABUDA D, MOGHRABI A, KRAJINOVIC M Pharmacogenomics in cancer treatment defining genetic bases for inter-individual differences in responses to chemotherapy. CURRENT OPINION IN PEDIATRICS 2007 vol. 19(1) pp. 15-22 ANSARI M, KRAJINOVIC M Pharmacogenomics of acute leukemia. PHARMACOGENOMICS 2007 vol. 8(7) pp. 817-834 ANSARI M, KRAJINOVIC M Research's domains TUMOR SUPPRESSOR GENE PHARMACOGENETICS STEM CELLS TRANSPLANTATION ONCOLOGY AND PEDIATRICS HEMATOLOGY ONCOGENTICS